CP and chronic myelogenous leukemia, BCR-ABL1 positive: Safety data reviewed by the adjudication committee reflect data collected as of February 6, 2017, with median follow-up of 37.3 months for all patients and 56.8 months (range 0.1–73.1 months) for CP-CML patients.